NCT04791007已完成早期 1 期
A Monocentric Phase I Safety, Acceptability, and Pharmacokinetic Trial of OB-002H Gel Administered Vaginally and Rectally in Open-Label and Randomised, Double- Blind, Placebo-Controlled Cohorts of HIV-1 Seronegative Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To evaluate the safety of OB-002H gel after single- and multiple-dose application based on the number of observed AEs
研究概览
简要总结
This is a monocentric phase I study in open-label and randomized, double-blind, placebo-controlled cohorts of HIV-1 seronegative adults to evaluate the safety, acceptability, and pharmacokinetic of OB-002H Gel administrated vaginally and rectally.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age between 18 and 45 years (inclusive).
- •HIV-1 antibody negative as documented at screening.
- •Understands and agrees to local sexually transmitted infection (STI) reporting requirements.
- •Able and willing to provide written informed consent to take part in the trial.
- •Willing and able to return for a follow-up visit one week after last IMP administration, barring unforeseen circumstances.
- •Of good general health in the opinion of the investigator.
- •Willing to be sexually abstinent (anal and vaginal sex) for 72 hours before and after each visit except Visit
- •No participation in other clinical trials within the last three months prior Visit 1 and throughout the trial.
- •Willing to abstain from inserting any non-trial products for rectal or vaginal application for 72 hours prior to each trial visit.
- •For female participants only:
- •Using (or willing to use) highly effective (i.e. failure rate <1% per year) methods of contraception for the duration of trial participation. Such methods include combined oral or transdermal hormonal contraception associated with inhibition of ovulation, oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD] or intrauterine hormone-releasing system [IUS] inserted at least 28 days prior to the Screening Visit, bilateral tubal occlusion, surgical sterilization, successful vasectomisation of male partner or sexually abstinent for the past 90 days and during the trial. If the female participant has female partners only, the method of contraception will be noted as abstinence to heterosexual activities in the trial documentation.
- •Not pregnant at the screening.
- •Not breastfeeding at screening nor intending to breastfeed during trial participation per participant report.
- •In addition, participants enrolled in the corresponding cohorts must meet the following criteria:
- •Cohorts A1 and B1 only: Willing to stay at the site overnight for two nights.
- •Cohort A2 only: Willing to stay at the site overnight for six nights.
- •Cohort A3 only: Willing to stay at the site overnight from Day 1 to Day 2 and from Day 5 to Day 6 for PK blood sampling.
排除标准
- •Following laboratory findings at screening:
- •Haemoglobin < 10.0 g/dL
- •Platelet count < 100 000/mm3
- •White blood cell count < 2 000 cells/mm3 or > 15 000 cells/mm3
- •Glomerular filtration rate (GFR) < 60 mL/min/1.73 m2
- •Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) > 2.5× laboratory upper limit of normal (ULN)
- •Abnormal glucose or protein on urinalysis (UA)
- •Known allergy or intolerance to any of the IMP excipients (sodium sorbate, sodium chloride, acetic acid, natrasol).
- •By participant report at screening: Use of post-exposure prophylaxis (PEP) for HIV exposure, systemic immunomodulatory medications vaginally or rectally administered medications, and vaginally or rectally administered products (including condoms) containing nonoxynol-9 (N-9) within the last four weeks prior to Visit
- •Any significant underlying medical condition or prior therapy that, in the opinion of the investigator, would preclude informed consent, make trial participation unsafe, make the individual unsuitable for the trial or unable to comply with the trial requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cardiovascular, immunological or cerebral disease.
- •Abnormalities of the cervical (females only), vaginal (females only), or colorectal mucosa, or significant symptom(s), which in the opinion of the clinician represents a contraindication to protocol-required biopsies (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external haemorrhoids).
- •Suspected or confirmed drug or alcohol abuse.
- •Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) test results. HSV-1 or HSV-2 seropositive diagnosis will only be allowed if no active lesions are present and since treatment is not required.
- •Body mass index (BMI) < 18 or > 30 kg/m
- •Previous enrolment to any preceding cohort of this trial.
- •Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
- •In addition to the criteria listed above, female participants will be excluded if they meet any of the following criteria:
- •Last pregnancy outcome or gynaecological surgery within 90 days prior to screening
- •Chronic and/or recurrent symptomatic vaginal candidiasis at screening
研究组 & 干预措施
Single dose administration (Part 1)
Experimental
the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
干预措施: OB-002 (Drug)
Multidose administration (Part 2)
Experimental
the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
干预措施: OB-002 (Drug)
Multidose administration (Part 2)
Experimental
the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
干预措施: Placebo (Drug)
结局指标
主要结局
To evaluate the safety of OB-002H gel after single- and multiple-dose application based on the number of observed AEs
时间窗: approximately 5 weeks for single dose and approximately five to seven weeks for multi-dose
For the primary safety analysis, the number of ≥ Grade 2 AEs, as well as the number and the percentage of participants with corresponding AEs, will be tabulated overall and per cohort, by system organ class (SOC) and by preferred term (PT). Additional AE analyses will also tabulate the number of AEs ≥ Grade 2 observed overall, by relationship and by severity. AEs ≥ Grade 2 that lead to discontinuation of trial participation will be tabulated separately. The safety set will be used for the primary safety analysis.
次要结局
- OB-002 serum concentration at different time points for the calculation of PK parameters (area under the concentration-time curve (AUC).(Serum samples collected within 24 hours after dosing)
- OB-002 serum concentration at different time points for the calculation of PK parameters (time to maximum concentration (tmax).(Serum samples collected within 24 hours after dosing)
- OB-002 serum concentration at different time points for the calculation of PK parameters (concentration half-life (t½).(Serum samples collected within 24 hours after dosing)
- OB-002 serum concentration at different time points for the calculation of PK parameters (maximum concentration (Cmax).(Serum samples collected within 24 hours after dosing)
- Acceptability(assessment done on the visit conducted 24 hours after IMP administration)
- OB-002 serum concentration at different time points for the calculation of PK parameters (minimum concentration (Cmin).(Serum samples collected within 24 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of HBV-001 D1 in Healthy AdultsDengue FeverNCT00936429Hawaii Biotech, Inc.16
进行中（未招募）
1 期
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Generalized Pustular PsoriasisNCT06433531Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.9
暂停
1 期
GPC3-CAR-T Cells for the Hepatocellular CarcinomaHepatocellular CarcinomaNCT04506983Beijing Tsinghua Chang Gung Hospital12
已完成
1 期
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsBRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanomaNCT05003622Pierre Fabre Medicament3
已完成
1 期
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)Prostate Cancer MetastaticNCT03490032Advanced Accelerator Applications30